For allogeneic cell therapy developers, donor availability is a critical factor. Without a donor, there is no therapy. Watch this webinar to learn how groundbreaking AI-based approaches, like the NMDPSM Donor Readiness Score, can predict the availability of every registered donor and evaluate the predictive power during donor selection. Our expert panel will explain how to: Predict an…
A client initiated a Phase I clinical trial for its allogeneic cell therapy. Several months in, limited success recruiting patients had led to an expensive lack of progress. The client engaged with the CIBMTR® Bioinformatics Consulting team through NMDP BioTherapies℠ to identify U.S. states and counties with the highest density of patients and donors with…
An NMDP BioTherapies℠ client was like many allogeneic cell and gene therapy developers. It was developing a therapy for a blood condition and needed to build an off-the-shelf bank of cryopreserved cell sources. The client needed to understand: HLA genotypes to cover most patients in the U.S. How many patients would be covered by cells…
Clinical trial sponsors and CROs have compelling reasons to design an effective clinical trial. You need to not only to answer your research question but also mitigate budget pressures and quickly bring a product to market that addresses patients’ chief complaints. In this webinar you’ll walk away with a better understanding of: Why the voice…
Cell therapy clinical trials—including those for hematopoietic cell transplantation (HCT)—come with unique challenges and complexity that impact the clinical trial sponsor, investigators, clinical trial sites, physicians, and patients and their caregivers. We offer comprehensive clinical trial services for academic and industry investigators and sponsors, as well as patients, because we know saving more lives through…